High Risk Smoldering Multiple Myeloma (HR-SMM)
Oncology·MeSH: Smoldering Multiple Myeloma
Prevalence
17.0 / 100K
Incidence
7.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2/Phase 3(1)
Frequently asked questions
How many drugs are in development for High Risk Smoldering Multiple Myeloma (HR-SMM)?
BioSniper tracks 1 drug in development for High Risk Smoldering Multiple Myeloma (HR-SMM) across 1 company.
How many clinical trials target High Risk Smoldering Multiple Myeloma (HR-SMM)?
There are 1 clinical trial targeting High Risk Smoldering Multiple Myeloma (HR-SMM) tracked by BioSniper.
What is the prevalence of High Risk Smoldering Multiple Myeloma (HR-SMM)?
The estimated prevalence of High Risk Smoldering Multiple Myeloma (HR-SMM) is approximately 17.0 per 100,000 population.
Deep-dive into High Risk Smoldering Multiple Myeloma (HR-SMM)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis